Find a Clinical Trial | American Lung Association

KEYMAKER-U01-01I

Researchers want to learn if study treatments that are antibody drug conjugates (ADCs) can treat metastatic squamous NSCLC that did not respond (get smaller or go away) to standard treatment. The main goals of this study are to learn about 1) the cancer response to the study treatments compared to chemotherapy and 2) the safety of the study treatments and if people tolerate them.

KEYMAKER-U01-01J

Researchers want to learn if using a study medicine called MK-1084 can help treat NSCLC. MK-1084 is a type of treatment called targeted therapy for the Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C gene change. The goal of this study is to learn about the safety of MK-1084 and to learn how many people have the cancer get smaller or go away during the study treatment.

Krascendo 2 (CO45042)

LAM-001 for PH-ILD

Studying inhaled sirolimus in PH-ILD patients

LUNAR-2

LUNG STAAR

The purpose of this research is to offer patients with centrally located early-stage non-small cell lung cancer (NSCLC) who are NOT candidates for surgery the opportunity to receive stereotactic body radiation therapy (SBRT).

MK-1084-004

This is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation and programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%.

MK-1084-007

The goal of this study is to learn if people who receive calderasib with SC pembrolizumab live longer without the cancer growing or spreading than in people who receive SC pembrolizumab with chemotherapy.

MK-2870-007

The primary objective of the study is to compare sacituzumab tirumotecan combined with pembrolizumab to pembrolizumab alone with respect to overall survival (OS).

MK-2870-019

This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response.

Next